Nuray Tynyshtykbayeva
Nuray Tynyshtykbayeva has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Ainur Akilzhanova
Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan
3 shared publications - Akbota Aitkulova
Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan
3 shared publications - Dos Sarbassov
Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan
3 shared publications - Asset Daniyarov
Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan
2 shared publications - Saule Rakhimova
National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan
2 shared publications - Assiya Kukanova
Astana Medical University
1 shared publication
Latest Publications
- 27 October 2026
- Published by National Center for Biotechnology in Eurasian Journal of Applied Biotechnology
- No. 4,p. 37-44
MICROSATELLITE INSTABILITY PROFILING WITH MSISENSOR2 IN WHOLE-EXOME SEQUENCING DATA FROM HEALTHY CONTROLS AND COLORECTAL CANCER PATIENTS
Microsatellite instability (MSI) is a molecular phenotype linked to defects in DNA mismatch repair (MMR) and serves as a biomarker in colorectal cancer (CRC). Computational MSI assessment using next-generation sequencing data enables characterisation of microsatellite instability without a dedicated MSI assay. This study evaluated MSIsensor2 scores in blood-derived whole-exome sequencing (WES) data from healthy individuals and two CRC patients. Whole-exome sequencing (WES) data from peripheral blood samples of 235 healthy Kazakh individuals were obtained from the DNA Biobank of the Laboratory of Genomic and Personalised Medicine, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan. Blood-derived WES data from two patients with CRC, designated BR110 and BR114, were also analysed. Sequencing libraries were prepared using Illumina workflows and sequenced on the NovaSeq 6000 platform. MSIsensor2 was employed to assess MSI scores and quantify the number of unstable microsatellite loci detected. Relationships among MSI scores, locus coverage, and sequencing data volume were examined descriptively. Of the 235 healthy individuals, 205 samples (87.2%) had MSI scores below 10%, while 30 samples (12.8%) had scores between 10% and 40% per study-specific classification. No sample exceeded 40%. The CRC-associated blood samples BR110 and BR114 demonstrated MSI scores of 5.43% and 7.81%, respectively. BR110 exhibited 10 unstable microsatellite sites among 184 covered sites, whereas BR114 had 26 among 333 covered sites. The higher score in BR114 corresponded with increased sequencing coverage and a greater number of evaluable loci. These findings indicate variability in computational MSI measurements across blood-derived WES datasets but do not establish tumour MSI status. MSIsensor2 produced MSI-associated measurements from blood-derived WES data in both healthy individuals and patients with CRC. However, MSI scores from blood sequencing do not necessarily reflect tumour status; therefore, determining the clinical relevance of these findings requires investigation using tumour-derived material, established MSI reference assays, and a larger clinical cohort.
- 27 October 2026
- Published by National Center for Biotechnology in Eurasian Journal of Applied Biotechnology
- No. 4,p. 37-44
MICROSATELLITE INSTABILITY PROFILING WITH MSISENSOR2 IN WHOLE-EXOME SEQUENCING DATA FROM HEALTHY CONTROLS AND COLORECTAL CANCER PATIENTS
Microsatellite instability (MSI) is a molecular phenotype linked to defects in DNA mismatch repair (MMR) and serves as a biomarker in colorectal cancer (CRC). Computational MSI assessment using next-generation sequencing data enables characterisation of microsatellite instability without a dedicated MSI assay. This study evaluated MSIsensor2 scores in blood-derived whole-exome sequencing (WES) data from healthy individuals and two CRC patients. Whole-exome sequencing (WES) data from peripheral blood samples of 235 healthy Kazakh individuals were obtained from the DNA Biobank of the Laboratory of Genomic and Personalised Medicine, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan. Blood-derived WES data from two patients with CRC, designated BR110 and BR114, were also analysed. Sequencing libraries were prepared using Illumina workflows and sequenced on the NovaSeq 6000 platform. MSIsensor2 was employed to assess MSI scores and quantify the number of unstable microsatellite loci detected. Relationships among MSI scores, locus coverage, and sequencing data volume were examined descriptively. Of the 235 healthy individuals, 205 samples (87.2%) had MSI scores below 10%, while 30 samples (12.8%) had scores between 10% and 40% per study-specific classification. No sample exceeded 40%. The CRC-associated blood samples BR110 and BR114 demonstrated MSI scores of 5.43% and 7.81%, respectively. BR110 exhibited 10 unstable microsatellite sites among 184 covered sites, whereas BR114 had 26 among 333 covered sites. The higher score in BR114 corresponded with increased sequencing coverage and a greater number of evaluable loci. These findings indicate variability in computational MSI measurements across blood-derived WES datasets but do not establish tumour MSI status. MSIsensor2 produced MSI-associated measurements from blood-derived WES data in both healthy individuals and patients with CRC. However, MSI scores from blood sequencing do not necessarily reflect tumour status; therefore, determining the clinical relevance of these findings requires investigation using tumour-derived material, established MSI reference assays, and a larger clinical cohort.
- Open Access
- 31 October 2024
- Published by Semey Medical University in Наука и здравоохранение
- No. 5(26),p. 221-229
CLINICAL RELEVANCE OF KRAS MUTATION TESTING IN METASTATIC COLORECTAL USING DIFFERENT SEQUENCING PLATFORMS: A CASE REPORT
Introduction. Colorectal cancer (CRC) ranks as the second leading cause of cancer mortality and the third most common cancer worldwide. Recent statistics reveal a troubling rise in CRC incidence among adults under 50 in high-income countries, with rates increasing 1-4% annually. While screening advancements, including colonoscopy, have improved early detection and survival rates, metastatic cases with KRASmutations remain challenging due to limited treatment options and mutation-driven resistance mechanisms. Aim. The present study aims to analyze the clinical significance of multi-platform verification of KRAS gene mutation in a particular clinical case in order to optimize personalized treatment strategies for patients with KRAS-positive metastatic colorectal cancer. Materials and methods. Our study reports the case of a 58-year-old female diagnosed with advanced-stage rectal adenocarcinoma with KRASmutation and multi-organ metastasis. Following partial intestinal obstruction, the patient underwent resection surgery with cholecystectomy and metastasectomy, followed by FOLFOX chemotherapy and targeted therapy (TT). Despite initial stabilization, metastasis progressed to the lungs and liver. Multiplatform genetic analysis, including Next generation sequencing (NovaSeq 6000), Sanger sequencing, and droplet digital PCR (ddPCR), was employed to confirm KRAS variant status, highlighting minor platform-based discrepancies with clinical relevance. Discussion. KRAS mutations profoundly affect CRC treatment strategies, particularly in relation to EGFR inhibitor eligibility. Multi-platform validation ensures accurate variant detection, critical for clinical decision-making. This case emphasizes the necessity of complementary assays, given the observed KRAS mutation’s influence on therapeutic outcomes. Cross-platform diagnostic guidelines are advocated to standardize detection thresholds and improve precision in treatment planning. Conclusion. This case underscores the clinical significance of multiplatform KRAS mutation validation in metastatic CRC, highlighting the potential for improved diagnostic protocols to optimize personalized treatment strategies for KRAS-mutant CRC patients. Актуальность. Колоректальный рак (КРР) является второй по значимости причиной смертности от рака и третьей по распространенности в мире. Последние статистические данные свидетельствуют о тревожном росте заболеваемости КРР среди взрослых в возрасте до 50 лет в странах с высоким уровнем дохода, причем показатели увеличиваются на 1-4% в год. В то время как достижения в области скрининга, включая колоноскопию, позволили улучшить раннее выявление и выживаемость, случаи метастазирования с мутациями KRAS остаются сложными из-за ограниченных возможностей лечения и механизмов резистентности, обусловленных мутациями. Цель. Настоящее исследование направлено на анализ клинической значимости много платформенной проверки мутации гена KRAS при частном клиническом случае с целью оптимизации персонализированных стратегий лечения пациентов с KRAS -позитивным метастатическим колоректальным раком. Материалы и методы. В данном исследовании сообщается о случае 58-летней женщины с диагнозом аденокарцинома прямой кишки на поздней стадии с мутацией KRAS и полиорганными метастазами. После частичной кишечной непроходимости пациентке была проведена резекция с холецистэктомией и удалением метастазов, а затем химиотерапия по методу FOLFOX и таргетная терапия (ТТ). Несмотря на первоначальную стабилизацию, метастазы прогрессировали в легких и печени. Для подтверждения статуса варианта KRAS был использован мультиплатформенный генетический анализ, включающий секвенирование следующего поколения (NovaSeq 6000), секвенирование по Сэнгеру и капельную цифровую ПЦР (ddPCR), что выявило незначительные несоответствия между платформами и клинической значимостью. Обсуждение. Мутации KRAS существенно влияют на стратегии лечения КРР, особенно в отношении приемлемости ингибиторов EGFR. Мультиплатформенная валидация обеспечивает точное выявление вариантов, что имеет решающее значение для принятия клинических решений. Данный случай подчеркивает необходимость дополнительных анализов, учитывая влияние мутации KRAS на результаты лечения. Рекомендуется использовать разные...
- 31 October 2024
- Published by Semey Medical University in Наука и здравоохранение
- No. 5(26),p. 221-229
Open AccessCLINICAL RELEVANCE OF KRAS MUTATION TESTING IN METASTATIC COLORECTAL USING DIFFERENT SEQUENCING PLATFORMS: A CASE REPORT
Introduction. Colorectal cancer (CRC) ranks as the second leading cause of cancer mortality and the third most common cancer worldwide. Recent statistics reveal a troubling rise in CRC incidence among adults under 50 in high-income countries, with rates increasing 1-4% annually. While screening advancements, including colonoscopy, have improved early detection and survival rates, metastatic cases with KRASmutations remain challenging due to limited treatment options and mutation-driven resistance mechanisms. Aim. The present study aims to analyze the clinical significance of multi-platform verification of KRAS gene mutation in a particular clinical case in order to optimize personalized treatment strategies for patients with KRAS-positive metastatic colorectal cancer. Materials and methods. Our study reports the case of a 58-year-old female diagnosed with advanced-stage rectal adenocarcinoma with KRASmutation and multi-organ metastasis. Following partial intestinal obstruction, the patient underwent resection surgery with cholecystectomy and metastasectomy, followed by FOLFOX chemotherapy and targeted therapy (TT). Despite initial stabilization, metastasis progressed to the lungs and liver. Multiplatform genetic analysis, including Next generation sequencing (NovaSeq 6000), Sanger sequencing, and droplet digital PCR (ddPCR), was employed to confirm KRAS variant status, highlighting minor platform-based discrepancies with clinical relevance. Discussion. KRAS mutations profoundly affect CRC treatment strategies, particularly in relation to EGFR inhibitor eligibility. Multi-platform validation ensures accurate variant detection, critical for clinical decision-making. This case emphasizes the necessity of complementary assays, given the observed KRAS mutation’s influence on therapeutic outcomes. Cross-platform diagnostic guidelines are advocated to standardize detection thresholds and improve precision in treatment planning. Conclusion. This case underscores the clinical significance of multiplatform KRAS mutation validation in metastatic CRC, highlighting the potential for improved diagnostic protocols to optimize personalized treatment strategies for KRAS-mutant CRC patients. Актуальность. Колоректальный рак (КРР) является второй по значимости причиной смертности от рака и третьей по распространенности в мире. Последние статистические данные свидетельствуют о тревожном росте заболеваемости КРР среди взрослых в возрасте до 50 лет в странах с высоким уровнем дохода, причем показатели увеличиваются на 1-4% в год. В то время как достижения в области скрининга, включая колоноскопию, позволили улучшить раннее выявление и выживаемость, случаи метастазирования с мутациями KRAS остаются сложными из-за ограниченных возможностей лечения и механизмов резистентности, обусловленных мутациями. Цель. Настоящее исследование направлено на анализ клинической значимости много платформенной проверки мутации гена KRAS при частном клиническом случае с целью оптимизации персонализированных стратегий лечения пациентов с KRAS -позитивным метастатическим колоректальным раком. Материалы и методы. В данном исследовании сообщается о случае 58-летней женщины с диагнозом аденокарцинома прямой кишки на поздней стадии с мутацией KRAS и полиорганными метастазами. После частичной кишечной непроходимости пациентке была проведена резекция с холецистэктомией и удалением метастазов, а затем химиотерапия по методу FOLFOX и таргетная терапия (ТТ). Несмотря на первоначальную стабилизацию, метастазы прогрессировали в легких и печени. Для подтверждения статуса варианта KRAS был использован мультиплатформенный генетический анализ, включающий секвенирование следующего поколения (NovaSeq 6000), секвенирование по Сэнгеру и капельную цифровую ПЦР (ddPCR), что выявило незначительные несоответствия между платформами и клинической значимостью. Обсуждение. Мутации KRAS существенно влияют на стратегии лечения КРР, особенно в отношении приемлемости ингибиторов EGFR. Мультиплатформенная валидация обеспечивает точное выявление вариантов, что имеет решающее значение для принятия клинических решений. Данный случай подчеркивает необходимость дополнительных анализов, учитывая влияние мутации KRAS на результаты лечения. Рекомендуется использовать разные...
- Open Access
- 26 June 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
Universal whole-genome Oxford nanopore sequencing of SARS-CoV-2 using tiled amplicons
We developed a comprehensive multiplexed set of primers adapted for the Oxford Nanopore Rapid Barcoding library kit that allows universal SARS-CoV-2 genome sequencing. This primer set is designed to set up any variants of the primers pool for whole-genome sequencing of SARS-CoV-2 using single- or double-tiled amplicons from 1.2 to 4.8 kb with the Oxford Nanopore. This multiplexed set of primers is also applicable for tasks like targeted SARS-CoV-2 genome sequencing. We proposed here an optimized protocol to synthesize cDNA using Maxima H Minus Reverse Transcriptase with a set of SARS-CoV-2 specific primers, which has high yields of cDNA template for RNA and is capable of long-length cDNA synthesis from a wide range of RNA amounts and quality. The proposed protocol allows whole-genome sequencing of the SARS-CoV-2 virus with tiled amplicons up to 4.8 kb on low-titer virus samples and even where RNA degradation has occurred. This protocol reduces the time and cost from RNA to genome sequence compared to the Midnight multiplex PCR method for SARS-CoV-2 genome sequencing using the Oxford Nanopore.
- 26 June 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
Open AccessUniversal whole-genome Oxford nanopore sequencing of SARS-CoV-2 using tiled amplicons
We developed a comprehensive multiplexed set of primers adapted for the Oxford Nanopore Rapid Barcoding library kit that allows universal SARS-CoV-2 genome sequencing. This primer set is designed to set up any variants of the primers pool for whole-genome sequencing of SARS-CoV-2 using single- or double-tiled amplicons from 1.2 to 4.8 kb with the Oxford Nanopore. This multiplexed set of primers is also applicable for tasks like targeted SARS-CoV-2 genome sequencing. We proposed here an optimized protocol to synthesize cDNA using Maxima H Minus Reverse Transcriptase with a set of SARS-CoV-2 specific primers, which has high yields of cDNA template for RNA and is capable of long-length cDNA synthesis from a wide range of RNA amounts and quality. The proposed protocol allows whole-genome sequencing of the SARS-CoV-2 virus with tiled amplicons up to 4.8 kb on low-titer virus samples and even where RNA degradation has occurred. This protocol reduces the time and cost from RNA to genome sequence compared to the Midnight multiplex PCR method for SARS-CoV-2 genome sequencing using the Oxford Nanopore.